Akari Therapeutics (AKTX) EBITDA (2014 - 2026)
Akari Therapeutics (AKTX) reported EBITDA of -$15.8 million for Q1 2026, down 347.04% on a YoY basis from $6.4 million in Q1 2025, and down 388.32% sequentially from -$3.2 million in Q4 2025.
Akari Therapeutics (AKTX) EBITDA (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 9 years of EBITDA data on file, last reported at -$15.8 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA fell 347.04% year-over-year to -$15.8 million; the trailing twelve-month figure through Mar 2026 stood at -$29.5 million (up 76.56% YoY), and the FY2025 full-year result was -$17.3 million, up 20.18% from the prior year.
- EBITDA fell to -$15.8 million in Q1 2026, from -$3.2 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$2.5 million in Q3 2023 to a low of -$112.0 million in Q4 2024.
- A 4-year average of -$13.7 million and a median of -$4.6 million in 2023 frame the typical range for EBITDA.
- Across the five-year window, EBITDA tumbled 2100.12% in 2024 and surged 97.12% in 2025, its largest moves.
- Tracing AKTX's EBITDA over 4 years: stood at -$5.1 million in 2023, then plunged by 2100.12% to -$112.0 million in 2024, then surged by 97.12% to -$3.2 million in 2025, then tumbled by 388.32% to -$15.8 million in 2026.
- Business Quant data shows AKTX's EBITDA at -$15.8 million in Q1 2026, -$3.2 million in Q4 2025, and -$7.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 268.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.76 Mn |
| Dec 31, 2025 | -3.23 Mn |
| Sep 30, 2025 | -7.40 Mn |
| Jun 30, 2025 | -3.12 Mn |
| Mar 31, 2025 | -3.53 Mn |
| Dec 31, 2024 | -111.99 Mn |
| Sep 30, 2024 | -2.93 Mn |
| Jun 30, 2024 | -7.45 Mn |
| Mar 31, 2024 | -5.99 Mn |
| Dec 31, 2023 | -5.09 Mn |
| Sep 30, 2023 | -2.51 Mn |
| Jun 30, 2023 | -4.62 Mn |
| Mar 31, 2023 | -4.59 Mn |
| Dec 31, 2020 | -6.90 Mn |
| Sep 30, 2020 | -246,883.00 |
| Jun 30, 2020 | -5.91 Mn |
| Mar 31, 2020 | -4.93 Mn |
| Dec 31, 2019 | -7.83 Mn |
| Sep 30, 2019 | -3.12 Mn |
| Jun 30, 2019 | -6.03 Mn |